We therefore performed a randomized, double-blind, placebo-controlled trial to determine whether use of a short-acting bronchodilator provides a protective effect in patients with COPD undergoing ...

Bronchodilators not only dilate the airway, but they also reduce hyperinflation during exercise and are invaluable in the treatment of COPD. Historically, short-acting beta2-agonists have been one ...

Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.

This pulmonary function test is used to diagnose lung diseases Spirometry, a type of pulmonary function test (PFT), is a ...

During the test, the doctor may also give you an inhaled bronchodilator ... using their quick-acting inhaler medicine before exercise. If an asthma attack makes you so short of breath that you ...

Discover the latest insights from the TOReTO study on COPD management: Dual bronchodilator therapy has been shown to reduce exacerbations, with varying efficacy between current and former smokers.

Traditionally, COPD management has relied on bronchodilators, pulmonary rehabilitation, steroids, and invasive options like lung transplantation or lung volume reduction surgery, leaving a gap in ...

Not studied in patients with acutely deteriorating asthma or COPD. Immediately reevaluate ... treat immediately with an inhaled, short-acting bronchodilator; discontinue Serevent Diskus ...

COPD may deteriorate acutely over a period ... it should be treated immediately with an inhaled, short-acting bronchodilator; umeclidinium should be discontinued immediately; and alternative ...

The Bronchodilator Drugs market in Central America is anticipated to witness a significant growth in revenue, with projections indicating that it will reach US$46.90m by 2024. Moreover ...

The Bronchodilator Drugs market in North Macedonia is expected to witness a substantial increase in revenue, reaching US$2.28m in 2024. Furthermore, it is projected that the market will exhibit a ...

a long-acting muscarinic antagonist (“LAMA”), supporting a nebulized fixed-dose combination program with ensifentrine for the maintenance treatment of COPD, and a trial assessing the efficacy ...